Article
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Mar 2011
Johnson David C, Corthals Sophie L, Walker Brian A, Ross Fiona M, Gregory Walter M, Dickens Nicholas J, Lokhorst Henk M, Goldschmidt Hartmut, Davies Faith E, Durie Brian G M, Van Ness Brian, Child J Anthony, Sonneveld Pieter, Morgan Gareth J
Abstract excerpt
PURPOSE: To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN). PATIENTS AND METHODS: We analyzed DNA from 1,495 patients with multiple myeloma. Using a custom-built single nucleotide polymorphism (SNP) array, we tested the association of TrPN with 3,404 SNPs. The SNPs were selected in predicted functional regions within 964 genes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
